Findings

What do systematic reviews say?

8 questions · 10 findings · 1 reviews · Vascular · Headline outcomes only

No studies found 5 · 50%GRADE not reported 1 · 10%Very low 1 · 10%Low 0 · 0%Moderate 1 · 10%High 2 · 20%

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Total VTE · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Total VTE · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Total VTE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy

It is very uncertain whether antithrombin changes any VTE compared with no thromboprophylaxis (very low certainty).

1 finding from 1 review

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Total VTE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).

1 finding from 1 review

Total VTE · ambulatory cancer patients receiving chemotherapy

DOAC probably leads to lower any VTE compared with placebo (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.55 [0.34, 0.9]
2 studies · 1404 participants
Moderate

Total VTE · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found